Credit: Getty Images. Real-world data conflict with a recent meta-analysis including patients from highly selected clinical trial populations. Although a recent meta-analysis suggested that ...

Use of a gonadotropin-releasing hormone antagonist is associated with lower risks for death than GnRH agonists, a systematic review and meta-analysis found. Use of degarelix, a gonadotropin-releasing ...

GENEVA, Switzerland December 17, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today ...

A pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the BRCA1/2 pathway. This is an ASCO Meeting Abstract from the 2020 ...

Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire ...

The first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for adults with advanced prostate cancer is now available in clinical practice. On December 18, 2020, the FDA approved ...

LONDON--(BUSINESS WIRE)--The European Commission (EC) has granted Marketing Authorization for Yselty® (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms ...

This release is also available in Chinese on EurekAlert! Chinese. With new information available, authors of a Cochrane Systematic Review have revised their conclusions about the relative ...

The world's first IVF baby, Louise Brown born in England in 1978, was conceived from a naturally developing follicle in her mother's ovary. However, as other groups around the world would quickly ...

In the majority of IVF cycles, whether using an agonist or an antagonist protocol, the trigger used is human chorionic gonadotropin (hCG), which shares a common subunit with LH and thus acts as a ...